HomefundingAntisense Pharma Receives €8M from MIG Funds and GAF

Antisense Pharma Receives €8M from MIG Funds and GAF


Antisense Pharma, a Regensburg, Germany-based biopharmaceutical company, has received an €8m equity investment from MIG Funds and GAF.

In addition, the current CEO, Dr. Karl-Hermann Schlingensiepen changed from the operative management of Antisense Pharma to a strategic advisory position closely associated with the company as of July 1. Until the successor is named, Dr. Hubert Heinrichs, Managing Director and Chief Medical Officer of Antisense Pharma, will assume this position as acting CEO.

The company focuses on targeted therapies for cancer diseases and is dedicated to discovering and developing drugs based on antisense technology for worldwide commercialization. As a targeted therapy, the Antisense medications specifically block the synthesis of key cancer proteins which cause the generation and the aggressive development of cancer diseases. Antisense Pharma has clinical trials running that involve patients with brain tumor, advanced pancreatic cancer, malignant melanoma and colorectal carcinoma.